Shareholder Vote

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549   FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2026     Amgen Inc. (Exact name of Registrant as Specified in Its Charter)     Delaware 001-37702 95-3540776 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.)           One Amgen Center Drive   Thousand Oaks , California   91320-1799 (Address of Principal Executive Offices)   (Zip Code)   Registrant’s Telephone Number, Including Area Code: (805) 447-1000     (Former Name or Former Address, if Changed Since Last Report)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common stock, $0.0001 par value   AMGN   The Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐   Item 5.07 Submission of Matters to a Vote of Security Holders. The Company held its Annual Meeting on May 19, 2026. The final results of the voting for each matter submitted to a vote of stockholders at the meeting are as follows: Item 1 - Election of Directors Each of the following 12 nominees for director were elected to serve a one-year term expiring at the Company’s 2027 annual meeting of stockholders and until his or her successor is elected and qualified, or until his or her earlier retirement, resignation, disqualification, removal or death.   Name Votes For Votes Against Abstain Broker Non-Votes Dr. Wanda M. Austin 408,261,366 4,136,960 541,141 63,739,635 Mr. Robert A. Bradway 390,137,618 20,492,559 2,309,290 63,739,635 Dr. Michael V. Drake 407,302,029 4,797,875 839,563 63,739,635 Dr. Brian J. Druker 409,304,364 3,054,075 581,028 63,739,635 Mr. Robert A. Eckert 393,137,908 19,206,011 595,548 63,739,635 Mr. Greg C. Garland 390,923,223 21,425,903 590,341 63,739,635 Mr. Charles M. Holley, Jr. 402,699,984 9,642,231 597,252 63,739,635 Dr. S. Omar Ishrak 408,204,077 4,139,152 596,238 63,739,635 Dr. Tyler Jacks 400,237,518 12,117,252 584,697 63,739,635 Dr. Mary E. Klotman 407,732,503 4,398,737 808,227 63,739,635 Ms. Ellen J. Kullman 405,340,175 6,775,403 823,889 63,739,635 Ms. Amy E. Miles 406,709,817 5,385,886 843,764 63,739,635   Item 2 - Advisor y Vote to A pprove Our Executive Compensation The advisory vote to approve our executive compensation was approved.    For: 399,315,381  Against: 11,987,682  Abstain: 1,636,404  Broker Non-Votes: 63,739,635   Item 3 - Ratification of Selection of Inde pendent Re gistered Public Accountants Ernst & Young LLP was ratified as the Company’s independent registered public accountants for the fiscal year ending December 31, 2026. No Broker Non-Votes resulted from the vote on this proposal.    For: 447,904,443  Against: 28,209,748  Abstain: 564,911   Item 4 - Stockholder Proposal to Require an Independent Board Chairman The stockholder proposal to require an independent board chairman was not approved.    For: 72,902,413  Against: 338,465,655  Abstain: 1,571,399  Broker Non-Votes: 63,739,635   No other matters were submitted for stockholder action.   SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.       AMGEN INC.         Date: May 20, 2026 By: /s/ Jonathan P. Graham       Name: Jonathan P. Graham       Title: Executive Vice President and General Counsel and Secretary